Matthew Resnick
Faculty Member

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

  1. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF (2013) J Comp Eff Res 2(4): 445-60
    › Primary publication · 24236685 (PubMed) · PMC4920086 (PubMed Central)
  2. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, Chang SS (2014) Urology 83(1): 75-80
    › Primary publication · 24231210 (PubMed)
  3. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Thompson IM, Kappa SF, Morgan TM, Barocas DA, Bischoff CJ, Keegan KA, Stratton KL, Clark PE, Resnick MJ, Smith JA, Cookson MS, Chang SS (2014) Urol Oncol 32(1): 45.e11-5
    › Primary publication · 24054870 (PubMed) · PMC4469381 (PubMed Central)
  4. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Chang SS (2014) BJU Int 113(6): 894-9
    › Primary publication · 24053444 (PubMed) · PMC3874077 (PubMed Central)
  5. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA, Chang SS (2014) J Urol 191(2): 329-34
    › Primary publication · 24036236 (PubMed)
  6. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Bekelman JE, Handorf EA, Guzzo T, Evan Pollack C, Christodouleas J, Resnick MJ, Swisher-McClure S, Vaughn D, Ten Have T, Polsky D, Mitra N (2013) Value Health 16(4): 610-8
    › Primary publication · 23796296 (PubMed) · PMC3694349 (PubMed Central)
  7. Urological cancer: walking the tightrope of survival and quality of life with ADT. Resnick MJ (2013) Nat Rev Clin Oncol 10(6): 307-8
    › Primary publication · 23648827 (PubMed)
  8. Management of superficial and muscle-invasive urothelial cancers of the bladder. Resnick MJ, Bassett JC, Clark PE (2013) Curr Opin Oncol 25(3): 281-8
    › Primary publication · 23425709 (PubMed)
  9. Long-term functional outcomes after treatment for localized prostate cancer. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) N Engl J Med 368(5): 436-45
    › Primary publication · 23363497 (PubMed) · PMC3742365 (PubMed Central)
  10. Quality of life with advanced metastatic prostate cancer. Resnick MJ, Penson DF (2012) Urol Clin North Am 39(4): 505-15
    › Primary publication · 23084527 (PubMed)